FDA warning letters – Pharma GMP

How to Handle a 483 Observation Without Panic

digi — Thu, 04 Sep 2025 22:11:34 +0000

How to Handle a 483 Observation Without Panic Effective Strategies to Handle FDA 483 Observations Calmly and Confidently Introduction: Why This Topic Matters for GMP Compliance During FDA inspections, investigators document potential violations of current Good Manufacturing Practice (cGMP) on Form 483. Receiving a 483 can be stressful for pharmaceutical manufacturers, but it is not...

Preparing for a Surprise FDA Inspection: Complete SOP

digi — Thu, 04 Sep 2025 04:07:32 +0000

Preparing for a Surprise FDA Inspection: Complete SOP Comprehensive SOP for Handling Surprise FDA Inspections Introduction: Why This Topic Matters for GMP Compliance FDA inspections are designed to ensure that pharmaceutical manufacturers consistently comply with Good Manufacturing Practices (GMP). While some inspections are pre-announced, many are unannounced or “surprise” inspections. These inspections test a company’s...

Root Cause Analysis for GMP Non-Conformities

digi — Wed, 03 Sep 2025 06:00:35 +0000

Root Cause Analysis for GMP Non-Conformities Effective Root Cause Analysis for GMP Non-Conformities Introduction: Why This Topic Matters for GMP Compliance Non-conformities in Good Manufacturing Practice (GMP) are inevitable in complex pharmaceutical manufacturing environments. Deviations, failures, and unexpected outcomes occur despite best efforts. Regulatory bodies such as the FDA, EMA, and WHO expect that when...

Top 10 GMP Violations Cited in USFDA Warning Letters

digi — Mon, 01 Sep 2025 22:15:00 +0000

Top 10 GMP Violations Cited in USFDA Warning Letters Most Frequent GMP Violations Highlighted in USFDA Warning Letters Introduction: Why This Topic Matters for GMP Compliance The United States Food and Drug Administration (USFDA) inspects pharmaceutical facilities worldwide to verify compliance with current Good Manufacturing Practices (cGMP). When critical deficiencies are found, the agency issues...